Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that Dr. Fahar Merchant, its President and CEO, will speak at the Oppenheimer 33rd Annual Healthcare Conference scheduled for March 14, 2023, at 2:40 PM ET. The event will take place virtually from March 13-15, 2023. Attendees can access the live webcast here. Medicenna is a clinical-stage immunotherapy company dedicated to developing innovative cancer treatments, including its lead product MDNA11 and the IL-4 Empowered Superkine, bizaxofusp, which has received FastTrack and Orphan Drug status.
- None.
- None.
TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference, which is scheduled to take place virtually from March 13 – 15, 2023.
Details on the fireside chat are as follows:
| Oppenheimer 33rd Annual Healthcare Conference | |
| Date: | Tuesday, March 14, 2023 |
| Time: | 2:40 PM ET |
| Webcast: | https://wsw.com/webcast/oppenheimer27/mdna/2750720 |
Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.
FAQ
When will Medicenna participate in the Oppenheimer 33rd Annual Healthcare Conference?
What time is Medicenna's presentation at the Oppenheimer Conference?
Where can I watch Medicenna's fireside chat?
What is MDNA's lead product?
What status has bizaxofusp received from the FDA?
